Bis and tris and tetra (4-{bis[4-(dimethylamino)phenyl]methylene}-N,N-dimethylcyclohexa-2,5-dien-1-iminium) [12,21-dihydro-29H,31H-phthalocyanine-bis and tris and tetrasulfonato-k4N29,N30,N31,N32]cuprate

Genetic toxicity: in vitro

Administrative data

Endpoint:

in vitro gene mutation study in bacteria

Remarks:

Type of genotoxicity: gene mutation

Type of information:

experimental study

Adequacy of study:

key study

Study period:

2011

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: see 'Remark'

Remarks:

The reliability is rated 1 because the study followed the standard guideline of reference (OECD 471), which describes a procedure designed to evaluate this endpoint, the results were reviewed for reliability and assessed as valid, and the study was conducted under GLP condition.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2011

Report date:

2011

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

OECD Guideline 471 (Bacterial Reverse Mutation Assay)

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Type of assay:

bacterial reverse mutation assay

Test material

Test material information

Constituent 1

Reference substance name:

Bis and tris and tetra (4-{bis[4-(dimethylamino)phenyl]methylene}-N,N-dimethylcyclohexa-2,5-dien-1-iminium) [12,21-dihydro-29H,31H-phthalocyanine-bis and tris and tetrasulfonato-k4N29,N30,N31,N32]cuprate

EC Number:

700-615-0

Molecular formula:

BIS: C82H74N14CuS2O6 TRIS: C107H103N17CuS3O9 TETRA: C132H132N20CuS4O12

IUPAC Name:

Bis and tris and tetra (4-{bis[4-(dimethylamino)phenyl]methylene}-N,N-dimethylcyclohexa-2,5-dien-1-iminium) [12,21-dihydro-29H,31H-phthalocyanine-bis and tris and tetrasulfonato-k4N29,N30,N31,N32]cuprate

Details on test material:

- Name of test material (as cited in study report): Sepisol Fast Violet 3B
- Substance type: organic
- Physical state: Violet powder
- Analytical purity: 100 %
- Lot/batch No.: 028942
- Storage condition of test material: TA (20 +/- 5°C). Hygroscopic

Method

Target gene:

histidine operon and tryptophan operon

Species / strain

Species / strain 1

Species / strain / cell type:

S. typhimurium TA 1535, TA 1537, TA 98 and TA 100

Species / strain 2

Species / strain / cell type:

E. coli WP2 uvr A pKM 101

Metabolic activation:

with and without

Metabolic activation system:

S9 mix

Test concentrations with justification for top dose:

0.5; 1.5; 5; 15; 50 µg/plate

Vehicle / solvent:

- solvent used: ethanol

Controls

Untreated negative controls:

yes

Negative solvent / vehicle controls:

yes

Positive controls:

yes

Details on test system and experimental conditions:

METHOD OF APPLICATION: in agar by direct incorporation or with pre-incubation for the second assay, if the first one is negative.

DURATION
- Preincubation period: 20 minutes
- Exposure duration: 48 to 72 hours
- Expression time (cells in growth medium):number of revertant colonies per plate

NUMBER OF REPLICATIONS: 1

NUMBER OF CELLS EVALUATED: 5 x 10 E 9

DETERMINATION OF CYTOTOXICITY
- Method: bacteriostatic activity

OTHER:
-Number of plates per assay: 3

Evaluation criteria:

R = (Number of revertant colonies wiith the test substance) / (Number of revertant colonies in the absence of the test substance)

Results and discussion

Test results

Test results 1

Species / strain:

S. typhimurium TA 1535, TA 1537, TA 98 and TA 100

Metabolic activation:

with and without

Genotoxicity:

negative

Cytotoxicity / choice of top concentrations:

cytotoxicity

Remarks:

bacteriostatic activity of 73-74 % at the 50 µg/plate dose

Vehicle controls validity:

valid

Untreated negative controls validity:

valid

Positive controls validity:

valid

Test results 2

Species / strain:

E. coli WP2 uvr A pKM 101

Metabolic activation:

with and without

Genotoxicity:

negative

Cytotoxicity / choice of top concentrations:

cytotoxicity

Remarks:

bacteriostatic activity of 73-74 % at the 50 µg/plate dose

Vehicle controls validity:

valid

Untreated negative controls validity:

valid

Positive controls validity:

valid

Additional information on results:

RANGE-FINDING/SCREENING STUDIES:
Cytotoxicity: Bacteriostatic activity of 74% was observed with 50 µg/plate of test material. This bacteriostatic activity stands below the tolerated threshold of 75%.
No cytotoxic effect observed for the other doses.

COMPARISON WITH HISTORICAL CONTROL DATA:
Rate of spontaneous revertants and positive controls (with and without S9 mix) fall within the range of observed historical values at the facility.

ADDITIONAL INFORMATION ON CYTOTOXICITY:
For all strains without metabolic activation and for TA 100- E.coli with metabolic activation, a significative decrease of the number of revertants colonies is observed for the dose of 50 µg/plate.This finding is in accordance with the bacteriostatic activity observed for this concentration

Any other information on results incl. tables

STRAIN	DOSE/PLATE (µg)	R
		Assay 1: - S9 mix 10%	Assay 1: + S9 mix 10%	Assay 2: - S9 mix 10%	Assay 2: + S9 mix 10% and pre-incubation
TA 1535	50	0.38	0.84	0.13	0.52
	15	0.96	0.65	0.26	0.65
	5	1.17	0.84	0.58	0.87
	1.5	1.33	1.00	0.81	1.03
	0.5	1.29	1.16	0.68	1.03
	Positive Control	89.81	14.19	57.75	4.95
TA 1537	50	0.33	2.46	0.10	1.41
	15	1.80	1.29	0.45	0.78
	5	2.40	1.14	0.80	1.15
	1.5	1.33	0.79	1.00	0.59
	0.5	1.20	0.93	1.00	0.85
	Positive Control	143.67	8.50	89.31	4.09
TA 98	50	0.60	1.31	0.61	0.94
	15	1.09	1.25	0.64	1.13
	5	1.04	1.01	1.00	0.99
	1.5	1.02	1.21	0.80	0.97
	0.5	1.02	1.00	0.95	0.77
	Positive Control	51.74	24.61	37.94	14.81
TA 100	50	0.38	0.62	0.34	0.56
	15	0.61	0.99	0.78	0.79
	5	0.73	1.05	1.14	0.89
	1.5	0.99	1.50	1.18	1.06
	0.5	0.94	1.26	1.08	1.00
	Positive Control	16.86	8.26	16.46	5.45
E.Coli	50	0.32	0.37	0.30	0.12
	15	0.46	0.42	0.41	0.32
	5	1.07	0.78	0.56	0.56
	1.5	0.97	1.02	0.94	0.86
	0.5	1.00	1.08	0.95	0.84
	Positive Control	10.29	7.54	14.31	6.52

R = (Number of revertant colonies in the presence of the test substance) / (Number of revertant colonies in the absence of the test substance)

Applicant's summary and conclusion

Conclusions:

Interpretation of results (migrated information):
negative

In the assay conditions, the differents concentrations of the test substance (50, 15, 5, 1.5 and 0.5 µg/plate), Sepisol Fast Violet 3B Lot n°028942 (LEMI code: EKT240111), provided by BIMA 83, does not induce any mutagenic change in Salmonella thyphimurium TA 1535, TA1537, TA98 and TA100 and Escherichia coli WP2(uvrA-) (pKM101) without or with metabolic activation according to the OECD Guidelines n°471 and to the method B13/B14 of the directive 200/32/EC.

Executive summary:

The assessment of the potential mutagenic activity of Sepisol Fast Violet 3B, was performed according to the Ames test (Salmonella His- and E.coli Trp- /microsome system) in compliance with the OECD Guideline 471 using the maximum tolerated concentration (standing below the threshold of 75%) recommended by OECD Guideline, i.e. 50μg/plate for this toxicity assay. Four lower dilutions were chosen according to a geometrical (half-log) ratio were also tested.

Preparation of test material solution

The test material (Sepisol Fast Violet 3B) is diluted in ethanol so as to prepare a stock solution of 2 mg/mL.

Preliminary assay: Cytotoxicity

Five concentrations were studied. 0.1 mL of the bacterial suspension from a culture containing 1 to 5 x 10⁹bacteria/mL and 0.1 mL of the different concentrations of the test substance were successively added to 2 mL of overlay agar at 45°C, containing 10% (v/v) of a solution of L-Histidine-D-Biotine (2.5mM). After homogeneization, the content of the tube was poured onto a Petri plate containing minimal agar (20 mL). 3 plates per concentration were incubated for 24 or 48 hours at 37°c, and the number of colonie counted.

A negative control containing the solvent alone was run in parallel.

Mutagenicity test

- Without metabolic activation:

Salmonella strains : for every strain, 0.1 mL of the bacterial suspension containing 1 to 5 x 10⁹bacteria/mL and 0.1 mL of every test substance concentration were successively added to 2 mL of overaly agar maintained surfusion in 45°C containing 10 % (v/v) of a L-Histidine-D-Biotin solution (0.5 mM).

E.Coli strain: in a test tube, 0.1 mL of the bacterial suspension containing 1 to 5 x 10⁹bacteria/mL and 0.1 mL of every test substance concentration were successively added to 2 mL of overaly agar maintained surfusion in 45°C containing 10 % (v/v) of Nutrient broth n°2 to which are added 5 µL of a L-Tryptophan solution at 2 mg/mL.

After homogeneization, the content of the tube was poured onto a Petri plate containing minimal agar (20 mL). 3 plates per concentration were incubated for 24 or 48 hours at 37°c, and the number of colonie counted.

- With metabolic activation :

Two techniques have been used:

- direct plate incorporation: Same technique to that described above, except that immediately before pouring the mixture onto the plates, 0.5 mL of 29 -mix metabolic activation system is quickly mixed,

- by pre-incubation: The test substance is preincubated with the test strain, and 0.5 mL of S9 -mix metabolic activation system at least for 20 min at 37°C prior to mixing with the overlay agar and pouring onto the surface of the minimal agar plate.

If the first assay gives a positive response, the incorporation plate method has been performed for the second S9 mix assay.

If the first assay gives a negative response, the pre-incubation method has been performed for the the second S9 mix assay.

Solvent controls, positive controls were performed like in the mutagenicity assay without and with metabolic activation.

Bacterioastatic activity

Bacterioastatic activity: Cytotoxic rate of 72% was observed with 50 µg/plate of test material. This rate stands below the tolerated

threshold of 75%. No cytotoxic effect observed for the other doses.

For all strains without metabolic activation and for TA 100- E.coli with metabolic activation, a significative decrease of the number of revertants colonies is observed for the dose of 50 µg/plate.This finding is in accordance with the bacteriostatic activity observed for this concentration.

Mutagenicity assays

The mutagenic activity of the test item was assessed by means of the Ames’s test in the four Salmonella typhimurium strains

TA1535, TA1537, TA98, TA100 and in the E. Coli WP2 (uvr A-) (pKM 101) tested either in presence or in absence of metabolic activation, in two independent assays. No mutagenic activity was found either with or without metabolic activation in any of the 5 strains. Values fall within the range of historical values observed at the facility.

For the Salmonella TA 1537 strain, an increase of the number of revertants at the 5; 15 and 50 µg/plate dose was observed. Nonetheless the mutagenic effet is only taken into account when the revertants' number is at least equal to 3 times the spontaneous revertant's rate for the TA 1537.

Conclusion

There is no significant difference between the number of spontaneous reversions, the number of reversions obtained in the positive controls (without and with metabolic activation), and the mean of corresponding exprimental historic values obtained in the laboratory.

There was no evidence of any increase in the number of revertant colonies in the presence of the test substance (50, 15, 5, 1.5 and 0.5 µg/plate) without and with metabolic activation for bacterial strains in Salmonella typhimurium TA1535, TA 1537, TA98, TA100 and Escherichia coli WP2(uvrA-) (pKM101). In presence of 50 µg/plate for all strains a signigficant decrease in revertant number was observed without metabolic activation and for TA100 and E.coli with metabolic activation. This is in accordance with the bacteriostatic activity observed for this concentration.

In the assay conditions, the differents concentrations of the test substance (50, 15, 5, 1.5 and 0.5 µg/plate), Sepisol Fast Violet 3B Lot n°028942 (LEMI code: EKT240111), provided by BIMA 83, does not induce any mutagenic change in Salmonella thyphimurium TA 1535, TA1537, TA98 and TA100 and Escherichia coli WP2(uvrA-) (pKM101) without or with metabolic activation according to the OECD Guidelines n°471 and to the method B13/B14 of the directive 200/32/EC.